Taipei-based biotech company Jyong Biotech Ltd. has leveraged a successful IPO to accelerate the development of MCS-2, a promising treatment for benign prostatic hyperplasia (BPH).
Spain’s Supreme Court ruled earlier this month that migrants intercepted at sea while attempting to reach Ceuta or Melilla cannot be summarily returned under the enclaves’ special border-rejecti